Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Wyeth: FDA second-guessing new drugs
With the FDA in CYA mode, drug makers are having to leap through more hoops to get their products approved--at least that's the opinion of Wyeth CEO Robert Essner and CEO-to-be Bernard Poussot. The two execs told Wall Street Journal's Health Blog that scandal-plagued drugs like Merck's Vioxx and GlaxoSmithKline's Avandia have prompted increased scrutiny for drug hopefuls like Wyeth's Pristiq, which failed to get the agency's nod this summer as the company hoped.
Still, Poussot says he's hopeful that Pristiq will get the OK--and that the approval will boost Wyeth stock. But that all depends on investors, who have their own fears to overcome.
- read the item from the Wall Street Journal
Related Articles:
Wyeth names Poussot CEO
FDA demands more data on Wyeth's Pristiq
Wyeth stumbles badly trying to develop new drugs
Wyeth buyout a good deal for Pfizer?
Wyeth stock down after several setbacks
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


